---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011311"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:59:05.161918+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dogwood Therapeutics Q2 net loss $3.8M; Halneuron Phase 2b interim data on track for Q4 2025

## Summary
- Enrolled 52 patients in Halneuron Phase 2b CINP trial; low discontinuation rate of 5.8% due to adverse events.
- R&D expenses $2.5M (up from $0.3M) driven by clinical trial costs; G&A $1.3M (up from $0.7M).
- Net loss $3.8M ($1.99 per share) vs $1.0M ($1.15) in Q2 2024; no revenue reported.
- Cash $13.4M expected to fund operations through Q1 2026; Halneuron fast-tracked by FDA.
- IMC-1 (fibromyalgia) ready for Phase 3; IMC-2 (Long-COVID) paused due to government funding uncertainty.

## SEC filing metadata
- accession: 0001558370-25-011311
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837025011311/0001558370-25-011311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837025011311/dwtx-20250813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011311
- JSON: https://secwatch.observer/filing/0001558370-25-011311.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011311.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.